Hims

Hims is a direct-to-consumer telehealth and health products company that serves men seeking convenient, discreet access to treatments for conditions that are frequently undertreated in traditional healthcare settings. The platform covers a range of men's health categories: weight loss (including GLP-1 medications), erectile dysfunction, hair loss, mental health (anxiety and depression), skincare, and sexual health. Hims operates on an asynchronous telehealth model. Patients complete detailed online health intakes rather than scheduling live video appointments, and licensed clinicians review responses to determine clinical candidacy. When approved, prescriptions are written and medications ship directly from licensed pharmacy partners to the patient's home. Ongoing management — prescription renewals, dosage questions, and clinical check-ins — is handled through the Hims mobile app. In the weight loss category, Hims offers compounded GLP-1 medications (semaglutide and tirzepatide) as its flagship products. Injectable formulations start at approximately $199/month, with oral GLP-1 options starting lower. Hims has been one of the more prominent platforms in the compounded GLP-1 space and has launched oral semaglutide formulations as a lower-barrier alternative to injectables. Hims does not accept health insurance for its services. However, all purchases are FSA and HSA eligible, and patients can request prescriptions be sent to a local pharmacy for potential insurance coverage on the medication side. This cash-pay model means pricing is transparent and consistent, though it may not be accessible to patients who depend on insurance coverage. Hims is a public company (NYSE: HIMS) and one of the most visible consumer health brands targeting men. Its sister brand Hers serves the same product categories for women and operates on the same platform and clinical infrastructure. depression), skincare, and sexual health. Hims operates on an asynchronous telehealth model. Patients complete detailed online health intakes rather than scheduling live video appointments, and licensed clinicians review responses to determine clinical candidacy. When approved, prescriptions are written and medications ship directly from licensed pharmacy partners to the patient's home. Ongoing management — prescription renewals, dosage questions, and clinical check-ins — is handled through the Hims mobile app. In the weight loss category, Hims offers compounded GLP-1 medications (semaglutide and tirzepatide) as its flagship products. Injectable formulations start at approximately $199/month, with oral GLP-1 options starting lower. Hims has been one of the more prominent platforms in the compounded GLP-1 space and has launched oral semaglutide formulations as a lower-barrier alternative to injectables. Hims does not accept health insurance for its services. However, all purchases are FSA and HSA eligible, and patients can request prescriptions be sent to a local pharmacy for potential insurance coverage on the medication side. This cash-pay model means pricing is transparent and consistent, though it may not be accessible to patients who depend on insurance coverage. Hims is a public company (NYSE: HIMS) and one of the most visible consumer health brands targeting men. Its sister brand Hers serves the same product categories for women and operates on the same platform and clinical infrastructure.